Ken Griffin Karyopharm Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.7 - $1.06 $10,920 - $16,536	-15,600 Reduced 19.6%	64,000 $53,000
Q2 2024 Aug 14, 2024	BUY	$0.87 - $1.58 $43,326 - $78,684	49,800 Added 167.11%	79,600 $69,000
Q1 2024 May 15, 2024	BUY	$0.72 - $1.66 $4,248 - $9,794	5,900 Added 24.69%	29,800 $44,000
Q4 2023 Feb 14, 2024	BUY	$0.68 - $1.31 $5,508 - $10,611	8,100 Added 51.27%	23,900 $20,000
Q3 2023 Nov 14, 2023	BUY	$1.14 - $1.81 $15,845 - $25,159	13,900 Added 731.58%	15,800 $21,000
Q2 2023 Aug 14, 2023	SELL	$1.79 - $4.59 $29,177 - $74,817	-16,300 Reduced 89.56%	1,900 $3,000
Q1 2023 May 15, 2023	SELL	$2.84 - $3.92 $192,836 - $266,168	-67,900 Reduced 78.86%	18,200 $70,000
Q4 2022 Feb 14, 2023	SELL	$2.48 - $5.93 $55,552 - $132,832	-22,400 Reduced 20.65%	86,100 $292,000
Q3 2022 Nov 14, 2022	SELL	$4.08 - $5.82 $6,936 - $9,894	-1,700 Reduced 1.54%	108,500 $592,000

57.6M

258K

81.2K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $62.2M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.